Nuclear coexpression of NF-κB subunit c-Rel and p53 mutants confers significantly poor survival in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: A Report from the International DLBCL Rituximab-CHOP Consortium
Publication
, Conference
Li, L; Xu-Monette, ZY; Ok, CY; Manyam, GC; Visco, C; Tzankov, A; Montes-Moreno, S; Dybkær, K; Chiu, A; Orazi, A; Zu, Y; Bhagat, G; Hsi, ED ...
Published in: Clinical Lymphoma Myeloma and Leukemia
June 2015
Duke Scholars
Published In
Clinical Lymphoma Myeloma and Leukemia
DOI
ISSN
2152-2650
Publication Date
June 2015
Volume
15
Start / End Page
S224 / S224
Publisher
Elsevier BV
Related Subject Headings
- 3211 Oncology and carcinogenesis
- 3201 Cardiovascular medicine and haematology
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Li, L., Xu-Monette, Z. Y., Ok, C. Y., Manyam, G. C., Visco, C., Tzankov, A., … Young, K. H. (2015). Nuclear coexpression of NF-κB subunit c-Rel and p53 mutants confers significantly poor survival in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: A Report from the International DLBCL Rituximab-CHOP Consortium. In Clinical Lymphoma Myeloma and Leukemia (Vol. 15, pp. S224–S224). Elsevier BV. https://doi.org/10.1016/j.clml.2015.04.101
Li, Ling, Zijun Y. Xu-Monette, Chi Y. Ok, Ganiraju C. Manyam, Carlo Visco, Alexander Tzankov, Santiago Montes-Moreno, et al. “Nuclear coexpression of NF-κB subunit c-Rel and p53 mutants confers significantly poor survival in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: A Report from the International DLBCL Rituximab-CHOP Consortium.” In Clinical Lymphoma Myeloma and Leukemia, 15:S224–S224. Elsevier BV, 2015. https://doi.org/10.1016/j.clml.2015.04.101.
Li L, Xu-Monette ZY, Ok CY, Manyam GC, Visco C, Tzankov A, et al. Nuclear coexpression of NF-κB subunit c-Rel and p53 mutants confers significantly poor survival in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: A Report from the International DLBCL Rituximab-CHOP Consortium. In: Clinical Lymphoma Myeloma and Leukemia. Elsevier BV; 2015. p. S224–S224.
Li, Ling, et al. “Nuclear coexpression of NF-κB subunit c-Rel and p53 mutants confers significantly poor survival in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: A Report from the International DLBCL Rituximab-CHOP Consortium.” Clinical Lymphoma Myeloma and Leukemia, vol. 15, Elsevier BV, 2015, pp. S224–S224. Crossref, doi:10.1016/j.clml.2015.04.101.
Li L, Xu-Monette ZY, Ok CY, Manyam GC, Visco C, Tzankov A, Montes-Moreno S, Dybkær K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WWL, Han van Krieken J, Huh J, Ponzoni M, Ferreri AJM, Farnen JP, Møller MB, Piris MA, Winter JN, Medeiros LJ, Young KH. Nuclear coexpression of NF-κB subunit c-Rel and p53 mutants confers significantly poor survival in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: A Report from the International DLBCL Rituximab-CHOP Consortium. Clinical Lymphoma Myeloma and Leukemia. Elsevier BV; 2015. p. S224–S224.
Published In
Clinical Lymphoma Myeloma and Leukemia
DOI
ISSN
2152-2650
Publication Date
June 2015
Volume
15
Start / End Page
S224 / S224
Publisher
Elsevier BV
Related Subject Headings
- 3211 Oncology and carcinogenesis
- 3201 Cardiovascular medicine and haematology
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences